Hengrui Medicine (600276.SH): HRS-5346 tablets receive drug clinical trial approval notice

Zhitong Finance APP news, Hengrui Pharmaceuticals (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration regarding HRS-5346 tablets, agreeing to conduct a Phase III clinical trial of this product. Indication applied for: reducing the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease accompanied by elevated lipoprotein(a) or at increased risk of a first cardiovascular event.